FONR Stock Rises Following Q3 Earnings on Higher Net Income

FONAR Corporation (FONR) shares have rallied following its fiscal Q3 2025 earnings release, which showed a 5.6% year-over-year increase in total net revenues to $27.2 million and a 25.8% jump in net income to $3.1 million, despite a slight dip in operating income; diluted net income per share rose 37% to $0.37. Revenue growth was driven by increases in management, service, and patient fees, while product sales declined, and the company cited record MRI scan volumes as a key factor; FONR is also executing a share repurchase program, having bought back 373,942 shares for $6.1 million as of March 31, 2025.

Analysis

FONAR Corporation (FONR) reported a strong fiscal third quarter for 2025, with shares rallying 15.4% post-earnings, significantly outperforming the S&P 500's 0.7% gain during the same period. Total net revenues increased 5.6% year-over-year to $27.2 million, driven by a 6.4% rise in management and other fees to $12.9 million, a notable 26.2% surge in service and repair fees to $2.3 million, and a 2.8% increase in patient fee revenues to $8.9 million; however, product sales declined by 50% to $55,000. Despite a 2.2% decrease in income from operations to $3.66 million, net income attributable to the company climbed 25.8% to $3.1 million, and diluted net income per common share surged 37% to $0.37, primarily due to a significantly lower income tax provision of $1 million compared to $1.8 million in the prior-year quarter. Operationally, FONAR's subsidiary, HMCA, achieved record MRI scan volumes, with 54,612 scans in Q3, a 3.4% year-over-year increase, reflecting growing demand and the success of its hybrid MRI model. The company is expanding this model with new high-field MRI installations. While total costs and expenses rose 6.9% to $23.5 million, the balance sheet remains healthy, with an improved current ratio of 10.0 and a 5% increase in net book value per share to $25.98. Operating cash flow for the nine months decreased to $7 million from $9.5 million, attributed to higher credit loss provisions and lower net receivables. FONAR continues its share repurchase program, having bought back $6.1 million worth of shares out of a $9 million authorization.

Key Decisions for Investors

• Investors should note the strong bottom-line performance and positive market reaction, driven by revenue growth in key service segments and a lower tax burden, but remain watchful of the slight decline in operating income.
• Monitor the impact of ongoing investments in high-field MRI units and the continued growth in scan volumes, as these are crucial for sustaining revenue momentum and offsetting the decline in product sales.
• Assess FONAR's ability to manage rising SG&A expenses and improve operating cash flow in future quarters, considering the recent pressures from provisioning and receivables.
• The ongoing share repurchase program and robust liquidity, evidenced by an improved current ratio, offer downside support and reflect management's confidence.